| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Medios AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €13.64 |
| 52 Week High | €13.64 |
| 52 Week Low | €13.64 |
| Beta | 1.09 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -72.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| MEDO.F | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | -1.4% | 1.6% |
| 1Y | n/a | 3.5% | 22.3% |
Return vs Industry: Insufficient data to determine how MEDO.F performed against the US Healthcare industry.
Return vs Market: Insufficient data to determine how MEDO.F performed against the US Market.
Price Volatility
| MEDO.F volatility | |
|---|---|
| MEDO.F Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 6.5% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: MEDO.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MEDO.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 500 | Matthias Gaertner | www.medios.ag |
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases.
Medios AG Fundamentals Summary
| MEDO.F fundamental statistics | |
|---|---|
| Market cap | US$411.97m |
| Earnings (TTM) | US$19.29m |
| Revenue (TTM) | US$1.94b |
21.4x
P/E Ratio0.2x
P/S RatioIs MEDO.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDO.F income statement (TTM) | |
|---|---|
| Revenue | €1.81b |
| Cost of Revenue | €1.70b |
| Gross Profit | €107.44m |
| Other Expenses | €89.47m |
| Earnings | €17.97m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 13, 2024
| Earnings per share (EPS) | 0.75 |
| Gross Margin | 5.94% |
| Net Profit Margin | 0.99% |
| Debt/Equity Ratio | 0% |
How did MEDO.F perform over the long term?
See historical performance and comparison